Duloxetine Capsule, Delayed Release
Product Images NDC 49252-007

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 49252-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Inventia Healthcare Limited., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 01

Chemical structure of duloxetine hydrochloride, showing its molecular arrangement including a naphthalene group, thiophene ring, and an amine group with HCl salt.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 02

A line chart comparing the proportion of patients with relapse over time in days post-randomization between placebo and duloxetine treatment groups. The y-axis represents the proportion of patients with relapse ranging from 0.0 to 1.0, while the x-axis shows time from randomization to relapse in days, ranging from 0 to 250.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 03

Kaplan-Meier curve showing the proportion of patients with relapse over time (days) comparing duloxetine treatment to placebo. The graph indicates lower relapse rates for duloxetine over approximately 250 days.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 04

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine 60 mg twice daily (BID), duloxetine 60 mg once daily (QD), duloxetine 20 mg QD, and placebo over a range of pain improvement percentages, with duloxetine groups showing higher patient improvement than placebo.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 05

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing duloxetine 60 mg BID, duloxetine 60 mg QD, and placebo. The graph shows patient improvement rates across various pain improvement percentages, with duloxetine treatments generally showing higher patient improvement compared to placebo.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 06

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BMCF). Two lines represent placebo and duloxetine 60/120 mg once daily, showing a general trend of decreasing percentage of patients improved as percent improvement in pain increases.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 07

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent treatment groups: placebo and duloxetine 60/120 mg once daily, with duloxetine showing a higher percentage of patients improved across various levels of pain improvement.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 08

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine (60/120 mg once daily). The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows percentage of patients improved. Two curves represent placebo (dotted line with crosses) and Duloxetine (solid line with diamonds), with Duloxetine showing higher patient improvement at most levels of pain improvement.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 09

A line graph comparing percentage improvement in pain from baseline between placebo and duloxetine 60 mg once daily. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine shows higher patient improvement percentages across most pain improvement levels compared to placebo.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 10

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) between placebo and duloxetine (60/120 mg once daily) groups, showing higher patient improvement with duloxetine across various pain improvement thresholds.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 11

Label for Duloxetine Delayed-Release Capsules USP 20 mg, a prescription oral capsule medication. The label shows a blister capsule image, states a 30 capsule count, and includes storage instructions. It lists Inventia Healthcare Limited as the manufacturer and distributor, with the product made in India.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 12

Label for Duloxetine Delayed-Release Capsules, USP 30 mg oral capsules in a 60-count package. The label shows the dosage strength, pharmacist dispensing instructions, storage conditions, and manufacturer Inventia Healthcare Limited, India. It includes barcodes and regulatory information.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 13

Label for Duloxetine Delayed-Release Capsules USP, 60 mg strength. The label indicates a 30-capsule package and includes usage instructions, storage conditions, manufacturer Information from Inventia Healthcare Limited, India, and a barcode. The label features branding with the Inventia logo and directions for dispensing to pharmacists.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 236 2

duloxetine 20 mg delayed release capsules in a blister pack. The blister holds 10 capsules arranged in two rows of five. The capsules are visually distinct with different half-colors, one dark and one orange. Labeler is Inventia Healthcare Limited.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 41 1

duloxetine 60 mg delayed release capsules image showing a single white opaque capsule with no visible markings, placed on a reflective surface, related to human prescription drug by Inventia Healthcare Limited.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 41 2

Packaging label of duloxetine delayed-release capsules in 20 mg, 30 mg, and 60 mg strengths. The label features the product name Duloxetine by Inventia Healthcare Limited. The capsules are shown in a blister packaging with the dosage strengths printed on the label.*

FDA Label Image

D633baad 41fe 491c A563 517d726028c6 41 3

The image shows a carton of duloxetine delayed-release capsules labeled with a strength of 60 mg. The packaging displays the brand name duloxetine prominently, indicating an oral dosage form. The labeler listed is Inventia Healthcare Limited. The carton includes the product name, strength, and dosage form on its visible panels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.